Parkinson's disease is one of the most prevalent neurodegenerative disorders. It is characterized by a progressive loss of dopaminergic neurons that leads to motor and cognitive decline and, ultimately, death. The accumulation of alpha-synuclein is a hallmark of the disease and, in some cases, it accumulates in structures called Lewy bodies. Mortalin reduces Lewy bodies toxicity and it has been shown to be downregulated in brain tissue samples of Parkinson's patients. In this study, the correlation of Mortalin and alpha-synuclein has been assessed in serum of Parkinson's patients using surface plasmon resonance. The results showed that Mortalin levels are lower in Parkinson's patients, contrary to alpha-synuclein, which was elevated in these same samples. Further statistical analysis confirmed the negative correlation between these two factors in samples from patients with Parkinson's disease. Overall, the researchers confirmed that Mortalin correlates with alpha-synuclein levels, making it a potential easily accessible serum biomarker for the diagnosis and monitoring of Parkinson's disease.
Serum Mortalin correlated with α-synuclein as serum markers in Parkinson’s disease: a pilot study
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!